Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 3

2760 - Comparative analysis of tumor mutational burden (TMB) prediction methods and its association with determinants of the tumor immune microenvironment of urothelial bladder cancer (UBC)


30 Sep 2019


Poster Display session 3


Tumour Site

Urothelial Cancer


Markus Eckstein


Annals of Oncology (2019) 30 (suppl_5): v356-v402. 10.1093/annonc/mdz249


M. Eckstein1, A. Hartmann2, P. Strissel3, R. Strick3, S. Wach4, H. Taubert4, B. Wullich4, C. Geppert1, V. Weyerer1, R. Stoehr1, M. Rübner3, P.A. Fasching5, S. Rabizadeh6, S. Benz6, F. Haller1, E. Moskalev1, L. Toegel1

Author affiliations

  • 1 Institute Of Pathology, Universitätsklinik Erlangen, 91054 - Erlangen/DE
  • 2 Institute Of Pathology, Universitätsklinik Erlangen, 91052 - Erlangen/DE
  • 3 Department Of Gynecology And Obstetrics, Universitätsklinik Erlangen, 91052 - Erlangen/DE
  • 4 Department Of Urology And Pediatric Urology, Universitätsklinik Erlangen, 91054 - Erlangen/DE
  • 5 Department Of Gynecology And Obstetrics, Universitätsklinik Erlangen, 91054 - Erlangen/DE
  • 6 N/a, NantCell, 90232 - Culver City/US


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 2760


TMB is an emerging biomarker for immune-therapy including metastasized UBC. The evaluation of reliable methods to determine the TMB value is a prerequisite for successful application of IO therapies.


TMB was assessed in genomic DNA from 39 muscle-invasive UBC by whole genome sequencing (GPS Cancer©, NantHealth). In 45 cases sequencing with the TruSight Oncology 500, (TSO500, Illumina) was performed. Immune cell (IC) infiltrates were analyzed by CD3, CD8, CD56, PD-1 and CD68 immunohistochemistry. PD-L1 status was evaluated by the SP263 assay (Ventana). Intrinsic subtypes (MDACC-approach) were assessed via a Nanostring-assay. Immune phenotypes were assessed by (I) spatial distribution of IC and (II) a T-cell inflammation related gene expression signature consisting of 29 genes (Nanostring). Results were validated in the TCGA MIBC cohort.


Correlation between TSO500 and WGS revealed high concordance (spearman-correlation: r = 0.68, p < 0.0001). Overall percentage agreement was 76.9% for a cut-off of 10 mut/mb and 84.6% for 15 mut/mb. We found no significant association of high TMB at different cut-offs (10 mut/mb, 15 mut/mb) with inflammation status and different immune cell populations in both cohorts. TMB was not associated with intrinsic subtypes. Spatially distributed IC phenotypes or PD-L1 status was not associated with TMB. Hierarchical clustering of all factors revealed four distinct subgroups: Cluster A Inflamed, PD-L1 “high”, TMB high (n = 5); Cluster B Inflamed, PD-L1 “high”, TMB low-intermediate (n = 14); Cluster C: Uninflamed, PD-L1 “low”, TMB intermediate-high (n = 14); Cluster D Uninflamed, PD-L1 “low”, TMB low (n = 12).


This study provides insights into the reliability of a NGS panel for the prediction of TMB in MIBC which shows comparable performance to WGS. High TMB seems to be a characteristic of MIBC which occurs regardless of PD-L1 and inflammation status. TMB could possibly identify additional patients who do not fulfill the PD-L1 assessment based criteria for checkpoint inhibition.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Illumina, California, United States of America NantHealth, Culver City, California, United States of America.


M. Eckstein: Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: AstraZeneca; Advisory / Consultancy: Janssen-Cilag. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.